
Nebilol2.5 mg
Opsonin Pharma Ltd.
Nebivolol Hydrochloride is a beta-1 selective adrenergic receptor blocker with additional vasodilating properties.
Nebivolol Hydrochloride is a beta-1 selective adrenergic receptor blocker with additional vasodilating properties. Its established and guideline-supported uses include:
Nebivolol Hydrochloride is not approved for acute decompensated heart failure or as first-line monotherapy in unstable cardiac conditions.
Dosing of Nebivolol Hydrochloride should be individualized and titrated according to patient response and tolerability.
| Indication | Population | Dosing |
|---|---|---|
| Hypertension | Adults | Initiate at 5 mg once daily; may be increased at 2-week intervals to 10 mg, 20 mg, and up to a maximum of 40 mg once daily as needed for blood pressure control. |
| Chronic heart failure (adjunct therapy) | Elderly adults (typically ≥70 years, in markets where approved) | Initiate at a very low dose (e.g., 1.25 mg once daily) with slow up-titration at 1-2 week intervals as tolerated, under close medical supervision, to a target maintenance dose. |
| Severe renal impairment (CrCl <30 mL/min) | Adults | Initiate at 2.5 mg once daily; titrate cautiously. |
| Moderate hepatic impairment | Adults | Initiate at 2.5 mg once daily; titrate cautiously. See Contraindications for severe hepatic impairment. |
| Pediatric use | Under 18 years | Safety and efficacy not established; not recommended. |
Discontinuation of Nebivolol Hydrochloride should always be gradual, tapering the dose over 1-2 weeks; see Precautions and Warnings.
Nebivolol Hydrochloride is generally well tolerated, with a favorable side-effect profile attributed to its vasodilating action. Reported adverse effects include:
Nebivolol Hydrochloride is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.